Participated · Equity · Oct 2025

Peer AI offers an agentic AI platform that generates and manages complex regulatory documents—such as protocols, clinical study reports, IND applications, investigator’s brochures, and plain-language summaries—while allowing medical writers to intervene at key control points. The system deploys specialized AI agents (data-source, authoring, style, and post-processing) within an intuitive interface to ensure accuracy, compliance, and consistency across more than 200,000 pages typically required for drug approval. Top-20 pharmaceutical companies and emerging biotechs are using the product to cut documentation drafting times by 55–94%, shrinking CSR preparation from 40 to 17 working days and reducing protocol turnaround from 6-8 weeks to one week. In the first three quarters of 2025, daily active usage tripled and overall platform volume grew six-fold, underscoring rapid adoption. Addressing an estimated $15 billion market, the company plans to invest in further product development and commercial expansion. Founded by industry veterans and headquartered in San Francisco, Peer AI has secured $12.1 million in venture funding to date.

Participated · Seed · Sep 2025

Trially AI has built a fully integrated, HIPAA-compliant platform that tackles the biggest bottleneck in clinical research—patient recruitment. Its core products include Trially Match, which analyzes unstructured EHR data to find eligible participants; Trially Connect, where the new agentic AI assistant “Margo” engages and pre-screens those candidates; and Trially Intelligence, a pipeline radar that flags suitable trials for a given patient population. The system can identify patients with roughly 95% screening accuracy, enroll 2–6× more patients per month in complex trials, reduce screen failures by 73%, and cut manual chart-review time by 91%. One research site network reported a $4 million revenue increase within three months of deployment, and users see as much as a 10× jump in identified trial candidates. The company positions itself for physicians, research sites, CROs, and pharmaceutical sponsors needing faster, more diverse enrollment. With fresh seed funding, management plans to accelerate platform adoption across research sites, sponsors, CROs, and physician networks. Financially, Trially AI has secured $4.7 million in seed capital to fuel this next phase of growth.